PMDS — PMD Device Solutions AB Share News
0.000.00%
Last trade - 00:00- SEK13.76m
- SEK40.59m
- SEK28.62m
Brief: Promore Pharma Q1 Net Loss Narrows To SEK 7.1 Mln
Brief: Promore Pharma Q1 Net Loss at SEK 7.1 Million
Brief: Promore Pharma Q4 Net Income at SEK -6.8 Million
Brief: Promore Pharma Q3 Net Loss Narrows To SEK 5.3 Mln
Brief: Promore Pharma Updates On Phase II Clinical Trial With Ensereptide
Brief: Promore Pharma Q2 Net Loss Narrows To SEK 6.1 Mln
Brief: Promore Pharma Granted EU Patent Regarding Treatment Of Chronic Wounds
Brief: Promore Pharma Q1 Operating Loss Widens To SEK 8.4 Mln
Brief: Promore Pharma Q4 Net Loss Narrows To SEK 5.7 Mln
Brief: Promore Pharma Granted US Patent Regarding Treatment Of Chronic Wounds
Brief: Promore Pharma Q3 Net Loss Narrows To SEK 6.1 Mln
Brief: Promore Pharma Q2 Net Loss Widens To SEK 7.9 Mln
Brief: Promore Pharma Receives SEK 48.6 Mln In Rights Issue
Brief: Promore Pharma Q1 Operating Loss Narrows To SEK 7.1 Mln
Brief: Promore Pharma Gets Patent Regarding Skin Scarring In U.S.
Brief: Promore Pharma Intends To Carry Out A Fully Secured Rights Issue
Brief: Promore Pharma Signs Agreement On Production Of Hyaluronic Acid With Italian Manufacturer Fidia
Brief: Promore Pharma Comments On Media Reports About Ensereptide
Brief: Promore Pharma Updates Its Strategy And Focuses On Scar Prevention